|
🐜
|
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
12 auth.
S. James,
A. Åkerblom,
C. Cannon,
H. Emanuelsson,
S. Husted,
H. Katus,
...
A. Skene,
P. Steg,
R. Storey,
R. Harrington,
R. Becker,
L. Wallentin
|
8 |
2009 |
8
🐜
|
|
🐜
|
Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
12 auth.
M. Fokkema,
S. James,
P. Albertsson,
A. Åkerblom,
F. Calais,
P. Eriksson,
...
J. Jensen,
T. Nilsson,
B. D. de Smet,
I. Sjögren,
B. Thorvinger,
B. Lagerqvist
|
7 |
2013 |
7
🐜
|
|
🐜
|
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
17 auth.
C. Varenhorst,
N. Eriksson,
Å. Johansson,
B. J. Barratt,
E. Hagström,
A. Åkerblom,
A. Syvänen,
R. Becker,
S. James,
H. Katus,
...
S. Husted,
P. Steg,
A. Siegbahn,
D. Voora,
R. Teng,
R. Storey,
L. Wallentin
|
6 |
2015 |
6
🐜
|
|
🐜
|
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
104 auth.
S. Zewinger,
M. Kleber,
V. Tragante,
R. McCubrey,
A. Schmidt,
K. Direk,
U. Laufs,
C. Werner,
Wolfgang Koenig,
D. Rothenbacher,
U. Mons,
L. Breitling,
H. Brenner,
Richard T. Jennings,
I. Petrakis,
...
S. Triem,
Mira Klug,
Alexandra Filips,
S. Blankenberg,
C. Waldeyer,
C. Sinning,
R. Schnabel,
K. Lackner,
E. Vlachopoulou,
O. Nygård,
G. Svingen,
E. Pedersen,
G. Tell,
J. Sinisalo,
M. Nieminen,
R. Laaksonen,
S. Trompet,
R. Smit,
N. Sattar,
J. Jukema,
H. Groesdonk,
G. Delgado,
T. Stojaković,
A. Pilbrow,
V. Cameron,
A. Richards,
R. Doughty,
Y. Gong,
R. Cooper-DeHoff,
Julie A. Johnson,
M. Scholz,
F. Beutner,
J. Thiery,
J. Smith,
Ragnar O. Vilmundarson,
R. McPherson,
A. Stewart,
S. Cresci,
P. Lenzini,
J. Spertus,
O. Olivieri,
D. Girelli,
N. Martinelli,
A. Leiherer,
C. Saely,
H. Drexel,
A. Mündlein,
P. Braund,
Christopher P. Nelson,
Nilesh J. Samani,
D. Kofink,
I. Hoefer,
G. Pasterkamp,
A. Quyyumi,
Y. Ko,
J. Hartiala,
H. Allayee,
W. Tang,
S. Hazen,
N. Eriksson,
C. Held,
E. Hagström,
L. Wallentin,
A. Åkerblom,
A. Siegbahn,
Igor Karp,
C. Labos,
L. Pilote,
J. Engert,
J. Brophy,
G. Thanassoulis,
P. Bogaty,
W. Szczeklik,
M. Kaczor,
M. Sanak,
S. Virani,
C. Ballantyne,
V. Lee,
E. Boerwinkle,
Michael V. Holmes,
B. Horne,
A. Hingorani,
F. Asselbergs,
R. Patel,
B. Krämer,
H. Scharnagl,
D. Fliser,
W. März,
T. Speer
|
6 |
2017 |
6
🐜
|
|
🦁
|
Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
7 auth.
A. Åkerblom,
S. James,
M. Koutouzis,
B. Lagerqvist,
U. Stenestrand,
B. Svennblad,
...
J. Oldgren
|
6 |
2010 |
6
🦁
|
|
🦁
|
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
14 auth.
A. Åkerblom,
L. Wallentin,
A. Siegbahn,
R. Becker,
A. Budaj,
Kristen Buck,
E. Giannitsis,
J. Horrow,
S. Husted,
H. Katus,
...
P. Steg,
R. Storey,
N. Åsenblad,
S. James
|
5 |
2012 |
5
🦁
|
|
🐜
|
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
10 auth.
M. Evans,
J. Carrero,
K. Szummer,
A. Åkerblom,
R. Edfors,
J. Spaak,
...
S. Jacobson,
P. Andell,
L. Lindhagen,
T. Jernberg
|
5 |
2016 |
5
🐜
|
|
🐜
|
Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study
16 auth.
J. Oldgren,
Sanna Laurila,
A. Åkerblom,
Aino Latva-Rasku,
E. Rebelos,
H. Isackson,
Maria Saarenhovi,
O. Eriksson,
K. Heurling,
E. Johansson,
...
U. Wilderäng,
C. Karlsson,
Russell L. Esterline,
E. Ferrannini,
J. Oscarsson,
P. Nuutila
|
5 |
2021 |
5
🐜
|
|
🐬
|
Oxypurines in cerebrospinal fluid as indices of disturbed brain metabolism. A clinical study of ischemic brain diseases.
R. Hallgren,
F. Niklasson,
A. Térent,
A. Åkerblom,
E. Widerlov
|
5 |
1983 |
5
🐬
|
|
🐜
|
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome
13 auth.
N. Pagidipati,
Connie N. Hess,
R. Clare,
A. Åkerblom,
P. Tricoci,
D. Wojdyla,
R. Keenan,
S. James,
C. Held,
K. Mahaffey,
...
A. Klein,
L. Wallentin,
M. Roe
|
5 |
2017 |
5
🐜
|
